Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Eloctate

Biogen Idec building

Biogen and Sobi’s Elocta wins EU approval

First haemophilia A treatment to offer prolonged protection against bleeding

- PMLiVE

Douglas Williams named president and CEO of Codiak

He joins from Biogen wherehe was executive VP of research and development

Executive vice president of Biogen leaves

Tony Kingsley departs the firm

Biogen Idec building

Biogen cuts workforce and culls pipeline projects

Attempts to make major cost savings as MS drug sales slow

- PMLiVE

BPL bags FDA approval for rare bleeding disorder therapy

First drug approved for hereditary Factor X deficiency

Novo launches online news channel for haemophilia patients

New medical information website aims to be a 'simple, centralised repository'

- PMLiVE

Genzyme opts into gene silencing therapy for haemophilia

Interim results show positive benefits for ALN-AT3

- PMLiVE

Bio investors react as Clinton tweet pledges pricing crackdown

Pharma companies come under scrutiny for pricing policies

Biogen’s Douglas Williams departs for biotech start-up

Research head will be first member of a new cancer-focused firm

- PMLiVE

Glimmer of hope for amyloid drugs in Alzheimer’s?

Expectations remain high but high efficacy rates still allusive for most firms

EISAI

Eisai to transfer US manufacturing campus to Biogen

Willhand over Research Triangle Park facility incapacity-sharing deal

- PMLiVE

Tantalising data for Baxter spin-off’s haemophilia therapy

Early-stage testing shows promise as a potentially transformative treatment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links